Amicus Therapeutics Is Offering Quality Therapies For Rare And Orphan Diseases

In America, the biotechnology industry is becoming highly competitive. Many biopharmaceutical companies are delivering quality therapies. However, only those that have the necessary resources and tools are thriving. Amicus Therapeutics is one of the leading biotechnology companies that are standing out in the industry. Amicus Therapeutics focuses on developing viable therapies for rare and orphan diseases, with a special attention to lysosomal storage disorders. Their broad portfolio of therapies targets various human genetic diseases. The company’s lead product candidate, migalastat, is a customized treatment that is in its late-stage of development. The drug targets patients diagnosed with Fabry disease based on their genetics.

Amicus Therapeutics’ SD-101, a product candidate, is also in the late-stage of development. It is a potential first-to-market drug for Epidermolysis Bullosa (EB). Their product development is largely based on Chaperone-Advanced Replacement Therapy (CHART™) platform technologies where they concentrate on the development of enzyme replacement therapies (ERT). In 2014, Amicus Therapeutics stood out as the company with “the broadest portfolio of small molecule pharmacological chaperones” in the industry. The company went public in 2007. Soon after, they expanded their operations by establishing their second research site in San Diego. Over the years, the corporation has received funding from the Michael J. Fox Foundation and the Alzheimer’s Drug Discovery Foundation to enhance their research activities. Amicus Therapeutics has registered steady growth, including the acquisition of Callidus Biopharma and Scioderm (http://weeklyopinion.com/2017/08/amicus-therapeutics-announces-the-launch-of-new-drug/).

The organization’s success in the highly competitive industry is an indicator of its exceptional leadership that promotes invention and healing. Amicus Therapeutics has achieved much growth under the leadership of John F. Crowley, the chairman and chief executive officer. Bradley has a sound background in the biotechnology industry. He has held high-ranking positions at Bristol-Myers Squibb, Novazyme Pharmaceuticals, and Genzyme Therapeutics. He graduated with a B.S. degree in foreign service from Georgetown University and earned a J.D. from the University of Notre Dame Law School. In addition, Crowley holds an MBA from Harvard University (YahooFinance). Crowley works closely with President and Chief Operating Officer Bradley L. Campbell to ensure that Amicus Therapeutics achieves its goals of developing quality therapies. With over 15 years of experience in the orphan drug industry, Bradley uses his vast knowledge to oversee the strategy, design and leadership of the company’s global commercial operations.

twitter

Osteo Relief Institute: Offering You Relief For Osteoarthritis

Arthritis is one of the most common chronic conditions for the 21st-century person. There are more than a hundred types of arthritis and affects more than fifty million people in the United States alone. The condition tends to affect aged people and is more frequent in women. The most common form of arthritis is that of the joints and is referred to as Osteoarthritis in medical terms. It typically leads to the deterioration of cartilage found in between the joints which leads to direct rubbing of the bones hence causing pain and swelling. It is caused by many factors such as being overweight, age, genetic setting and even a prior joint injury. Fortunately, according to Dr. Matthew CiRullo from Osteo Relief Institute, there are many treatment options for a person suffering from this form of arthritis, and it is also self-manageable. Also, there are exercises which you can do to cure it. For instance, low impact ones such as walking, swimming or even cycling help a lot. Also, avoid smoking, and don’t engage in activities which are beyond your capabilities. Seek medication, and if it’s a case of severe arthritis, surgery may be the only option.

About Osteo relief institute

Osteoarthritis is a problem that hundreds of people across the world go through every day and finding a facility which specializes in its treatment is a challenging task. That is the main reason why the New Jersey-based company known as Osteo relief institute was built. The facility which began in 2011, boasts state of the art pieces of equipment and highly trained professionals who work themselves to the finger bone to ensure that they relieve you the pain that comes with arthritis without necessarily having to use surgery (About). Each facility has independent ownership and is fully certified with FDA approval. The Osteo relief institute takes the extra mile in helping you get the care that you need by going through your entire medical history first before taking any other step. This together with the use of modern technology places the professional in charge of your treatment is in a better spot to know the right diagnosis for your Osteoarthritis.